Summary
46.29 -0.23(-0.49%)09/16/2024
Inari Medical Inc (NARI)
Inari Medical Inc (NARI)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.49 | 3.63 | -5.88 | 7.05 | 11.33 | -29.92 | 0.00 | 8.89 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 46.29 | |
| Open | 46.25 | |
| High | 46.57 | |
| Low | 45.09 | |
| Volume | 631,418 | |
| Change | -0.23 | |
| Change % | -0.49 | |
| Avg Volume (20 Days) | 691,754 | |
| Volume/Avg Volume (20 Days) Ratio | 0.91 | |
| 52 Week Range | 36.73 - 69.35 | |
| Price vs 52 Week High | -33.25% | |
| Price vs 52 Week Low | 26.03% | |
| Range | 0.09 | |
| Gap Up/Down | -0.60 | |
Fundamentals | ||
| Market Capitalization (Mln) | 2,711 | |
| EBIDTA | 28,293,000 | |
| PE Ratio | 281.5141 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 121.00 | |
| Book Value | 4.6740 | |
| Earnings Per Share | 0.2840 | |
| EPS Estimate Current Quarter | -0.1100 | |
| EPS Estimate Next Quarter | 0.0200 | |
| EPS Estimate Current Year | 0.1700 | |
| EPS Estimate Next Year | 0.2700 | |
| Diluted EPS (TTM) | 0.2840 | |
| Revenues | ||
| Profit Marging | 0.0649 | |
| Operating Marging (TTM) | 0.1062 | |
| Return on asset (TTM) | 0.0646 | |
| Return on equity (TTM) | 0.0738 | |
| Revenue TTM | 242,376,992 | |
| Revenue per share TTM | 4.9000 | |
| Quarterly Revenue Growth (YOY) | 0.8830 | |
| Quarterly Earnings Growth (YOY) | 0.4440 | |
| Gross Profit (TTM) | 127,799,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 281.5141 | |
| Forward PE | 1,250.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 16.9227 | |
| Revenue Enterprise Value | 15.8141 | |
| EBITDA Enterprise Value | 197.7499 | |
| Shares | ||
| Shares Outstanding | 50,204,800 | |
| Shares Float | 37,801,170 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 20.09 | |
| Institutions (%) | 82.80 | |
09/13 09:26 EST - zacks.com
Reasons to Retain Inari Medical Stock in Your Portfolio for Now
NARI continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.
Reasons to Retain Inari Medical Stock in Your Portfolio for Now
NARI continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.
08/29 16:05 EST - globenewswire.com
Inari Medical Announces PEERLESS Data to be Presented During the Late-Breaking Clinical Trial Sessions at TCT 2024
IRVINE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that data from the PEERLESS trial will be presented by Dr. Wissam Jaber, Professor of Medicine at Emory University School of Medicine, during the Late-Breaking Clinical Trial Sessions at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium in Washington, D.C. The presentation will take place on October 29th.
Inari Medical Announces PEERLESS Data to be Presented During the Late-Breaking Clinical Trial Sessions at TCT 2024
IRVINE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that data from the PEERLESS trial will be presented by Dr. Wissam Jaber, Professor of Medicine at Emory University School of Medicine, during the Late-Breaking Clinical Trial Sessions at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium in Washington, D.C. The presentation will take place on October 29th.
08/26 12:35 EST - zacks.com
Inari Medical (NARI) Issues Notice Post ClotTriever XL Recall
Inari Medical (NARI) issues urgent updates to ClotTriever XL Catheter instructions following the FDA's recall after reports of serious injuries and deaths.
Inari Medical (NARI) Issues Notice Post ClotTriever XL Recall
Inari Medical (NARI) issues urgent updates to ClotTriever XL Catheter instructions following the FDA's recall after reports of serious injuries and deaths.
08/21 16:05 EST - globenewswire.com
Inari Medical to Present at Upcoming Investor Conferences
IRVINE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will present at the following investor conferences:
Inari Medical to Present at Upcoming Investor Conferences
IRVINE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will present at the following investor conferences:
07/31 14:30 EST - investorplace.com
7 Leading MedTech Stocks for Next-Gen Health Solutions
While technology lately has been framed in the context of computer hardware or software, it can also apply to the broader field of medicine. Therefore, investors should consider the viable field of MedTech stocks.
7 Leading MedTech Stocks for Next-Gen Health Solutions
While technology lately has been framed in the context of computer hardware or software, it can also apply to the broader field of medicine. Therefore, investors should consider the viable field of MedTech stocks.
07/31 13:11 EST - zacks.com
Inari Medical (NARI) Q2 Earnings Miss, Revenues Increase Y/Y
Inari Medical's (NARI) second-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the company continues to incur operating losses.
Inari Medical (NARI) Q2 Earnings Miss, Revenues Increase Y/Y
Inari Medical's (NARI) second-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the company continues to incur operating losses.
07/30 21:53 EST - seekingalpha.com
Inari Medical, Inc. (NARI) Q2 2024 Earnings Call Transcript
Start Time: 16:30 January 1, 0000 2:24 PM ET Inari Medical, Inc. (NASDAQ:NARI ) Q2 2024 Earnings Conference Call July 30, 2024, 16:30 PM ET Company Participants Drew Hykes - President and CEO Mitch Hill - CFO Tom Tu - Chief Medical Officer Kevin Strange - SVP of Finance, Accounting, Strategy and Business Development Marissa Bych - Gilmartin Group LLC Conference Call Participants Kallum Titchmarsh - Morgan Stanley Stephanie Pezzi - Bank of America Marie Thibault - BTIG Bill Plovanic - Canaccord Chris Pasquale - Nephron Research Adam Maeder - Piper Sandler Richard Newitter - Truist Margaret Kaczor - William Blair Operator Good afternoon, everyone, and welcome to the Inari Medical, Inc. Second Quarter 2024 Earnings Conference Call. All participants are in a listen-only mode.
Inari Medical, Inc. (NARI) Q2 2024 Earnings Call Transcript
Start Time: 16:30 January 1, 0000 2:24 PM ET Inari Medical, Inc. (NASDAQ:NARI ) Q2 2024 Earnings Conference Call July 30, 2024, 16:30 PM ET Company Participants Drew Hykes - President and CEO Mitch Hill - CFO Tom Tu - Chief Medical Officer Kevin Strange - SVP of Finance, Accounting, Strategy and Business Development Marissa Bych - Gilmartin Group LLC Conference Call Participants Kallum Titchmarsh - Morgan Stanley Stephanie Pezzi - Bank of America Marie Thibault - BTIG Bill Plovanic - Canaccord Chris Pasquale - Nephron Research Adam Maeder - Piper Sandler Richard Newitter - Truist Margaret Kaczor - William Blair Operator Good afternoon, everyone, and welcome to the Inari Medical, Inc. Second Quarter 2024 Earnings Conference Call. All participants are in a listen-only mode.
07/30 18:46 EST - zacks.com
Inari Medical, Inc. (NARI) Reports Q2 Loss, Tops Revenue Estimates
Inari Medical, Inc. (NARI) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to earnings of $0.04 per share a year ago.
Inari Medical, Inc. (NARI) Reports Q2 Loss, Tops Revenue Estimates
Inari Medical, Inc. (NARI) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to earnings of $0.04 per share a year ago.
07/30 16:10 EST - globenewswire.com
Inari Medical Announces Chief Financial Officer Retirement and Succession Plan
Mitch Hill to retire as Chief Financial Officer, to be succeeded by Kevin Strange in October 2024 Mitch Hill to retire as Chief Financial Officer, to be succeeded by Kevin Strange in October 2024
Inari Medical Announces Chief Financial Officer Retirement and Succession Plan
Mitch Hill to retire as Chief Financial Officer, to be succeeded by Kevin Strange in October 2024 Mitch Hill to retire as Chief Financial Officer, to be succeeded by Kevin Strange in October 2024
07/23 11:06 EST - zacks.com
Inari Medical, Inc. (NARI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Inari Medical (NARI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inari Medical, Inc. (NARI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Inari Medical (NARI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
07/16 16:05 EST - globenewswire.com
Inari Medical to Announce Second Quarter 2024 Financial Results
IRVINE, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its second quarter 2024 financial results on Tuesday, July 30, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
Inari Medical to Announce Second Quarter 2024 Financial Results
IRVINE, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its second quarter 2024 financial results on Tuesday, July 30, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
07/12 14:45 EST - accesswire.com
Inari Medical, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 12, 2024 to Discuss Your Rights - NARI
NEW YORK, NY / ACCESSWIRE / July 12, 2024 / If you suffered a loss on your Inari Medical, Inc. (NASDAQ:NARI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/inari-medical-inc-lawsuit-submission-form?prid=90574&wire=1 or contact Joseph E. Levi, Esq.
Inari Medical, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 12, 2024 to Discuss Your Rights - NARI
NEW YORK, NY / ACCESSWIRE / July 12, 2024 / If you suffered a loss on your Inari Medical, Inc. (NASDAQ:NARI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/inari-medical-inc-lawsuit-submission-form?prid=90574&wire=1 or contact Joseph E. Levi, Esq.
07/12 14:28 EST - globenewswire.com
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Inari Medical, Inc. – NARI
NEW YORK, July 12, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Inari Medical, Inc. (“Inari” or the “Company”) (NASDAQ: NARI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Inari Medical, Inc. – NARI
NEW YORK, July 12, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Inari Medical, Inc. (“Inari” or the “Company”) (NASDAQ: NARI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
07/12 12:30 EST - accesswire.com
Investors in Inari Medical, Inc. Should Contact Levi & Korsinsky Before July 12, 2024 to Discuss Your Rights - NARI
NEW YORK, NY / ACCESSWIRE / July 12, 2024 / If you suffered a loss on your Inari Medical, Inc. (NASDAQ:NARI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/inari-medical-inc-lawsuit-submission-form?prid=90550&wire=1 or contact Joseph E. Levi, Esq.
Investors in Inari Medical, Inc. Should Contact Levi & Korsinsky Before July 12, 2024 to Discuss Your Rights - NARI
NEW YORK, NY / ACCESSWIRE / July 12, 2024 / If you suffered a loss on your Inari Medical, Inc. (NASDAQ:NARI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/inari-medical-inc-lawsuit-submission-form?prid=90550&wire=1 or contact Joseph E. Levi, Esq.
07/12 12:00 EST - accesswire.com
Shareholders that lost money on Inari Medical, Inc. (NARI) should contact Levi & Korsinsky about pending Class Action - NARI
NEW YORK, NY / ACCESSWIRE / July 12, 2024 / If you suffered a loss on your Inari Medical, Inc. (NASDAQ:NARI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/inari-medical-inc-lawsuit-submission-form?prid=90545&wire=1 or contact Joseph E. Levi, Esq.
Shareholders that lost money on Inari Medical, Inc. (NARI) should contact Levi & Korsinsky about pending Class Action - NARI
NEW YORK, NY / ACCESSWIRE / July 12, 2024 / If you suffered a loss on your Inari Medical, Inc. (NASDAQ:NARI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/inari-medical-inc-lawsuit-submission-form?prid=90545&wire=1 or contact Joseph E. Levi, Esq.
07/12 12:00 EST - accesswire.com
FINAL NARI DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Inari Medical, Inc. Investors to Join the Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / July 12, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Inari securities between March 10, 2021 and February 28, 2024, inclusive (the "Class Period").
FINAL NARI DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Inari Medical, Inc. Investors to Join the Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / July 12, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Inari securities between March 10, 2021 and February 28, 2024, inclusive (the "Class Period").
07/12 11:15 EST - accesswire.com
Shareholders that Lost Money on Inari Medical, Inc.(NARI) Should Contact Levi & Korsinsky About Pending Class Action - NARI
NEW YORK, NY / ACCESSWIRE / July 12, 2024 / If you suffered a loss on your Inari Medical, Inc. (NASDAQ:NARI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/inari-medical-inc-lawsuit-submission-form?prid=90529&wire=1 or contact Joseph E. Levi, Esq.
Shareholders that Lost Money on Inari Medical, Inc.(NARI) Should Contact Levi & Korsinsky About Pending Class Action - NARI
NEW YORK, NY / ACCESSWIRE / July 12, 2024 / If you suffered a loss on your Inari Medical, Inc. (NASDAQ:NARI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/inari-medical-inc-lawsuit-submission-form?prid=90529&wire=1 or contact Joseph E. Levi, Esq.
07/12 11:00 EST - accesswire.com
The Schall Law Firm Calls On Shareholders Who Suffered Losses In Inari Medical Inc To Start Conversation As It Begins A Probe
LOS ANGELES, CA / ACCESSWIRE / July 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 24, 2022 and February 28, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before July 12, 2024.
The Schall Law Firm Calls On Shareholders Who Suffered Losses In Inari Medical Inc To Start Conversation As It Begins A Probe
LOS ANGELES, CA / ACCESSWIRE / July 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 24, 2022 and February 28, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before July 12, 2024.
07/12 10:45 EST - accesswire.com
Levi & Korsinsky Reminds Inari Medical, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 12, 2024 - NARI
NEW YORK, NY / ACCESSWIRE / July 12, 2024 / If you suffered a loss on your Inari Medical, Inc. (NASDAQ:NARI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/inari-medical-inc-lawsuit-submission-form?prid=90523&wire=1 or contact Joseph E. Levi, Esq.
Levi & Korsinsky Reminds Inari Medical, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 12, 2024 - NARI
NEW YORK, NY / ACCESSWIRE / July 12, 2024 / If you suffered a loss on your Inari Medical, Inc. (NASDAQ:NARI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/inari-medical-inc-lawsuit-submission-form?prid=90523&wire=1 or contact Joseph E. Levi, Esq.
07/12 10:20 EST - globenewswire.com
NARI Investors Have Opportunity to Lead Inari Medical, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, July 12, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Inari Medical, Inc. (“Inari” or “the Company”) (NASDAQ: NARI ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 24, 2022 and February 28, 2024, inclusive (the “Class Period”), are encouraged to contact the firm before July 12, 2024.
NARI Investors Have Opportunity to Lead Inari Medical, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, July 12, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Inari Medical, Inc. (“Inari” or “the Company”) (NASDAQ: NARI ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 24, 2022 and February 28, 2024, inclusive (the “Class Period”), are encouraged to contact the firm before July 12, 2024.